Jeffrey Farrow Sells 14,396 Shares of Tarsus Pharmaceuticals (NASDAQ:TARS) Stock

Posted by on Jun 17th, 2026

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Get Free Report) insider Jeffrey Farrow sold 14,396 shares of the business’s stock in a transaction that occurred on Tuesday, June 16th. The stock was sold at an average price of $60.95, for a total value of $877,436.20. Following the completion of the sale, the insider directly owned 56,801 shares in the company, valued at approximately $3,462,020.95. This represents a 20.22% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Tarsus Pharmaceuticals Stock Up 2.9%

Shares of Tarsus Pharmaceuticals stock traded up $1.75 during midday trading on Wednesday, hitting $62.55. The company had a trading volume of 462,278 shares, compared to its average volume of 606,366. Tarsus Pharmaceuticals, Inc. has a 52-week low of $38.51 and a 52-week high of $85.25. The company has a debt-to-equity ratio of 0.21, a quick ratio of 3.71 and a current ratio of 3.74. The stock has a market capitalization of $2.69 billion, a P/E ratio of -54.87 and a beta of 0.49. The company has a 50 day moving average of $63.62 and a 200 day moving average of $69.67.

Tarsus Pharmaceuticals (NASDAQ:TARS – Get Free Report) last announced its quarterly earnings data on Wednesday, May 6th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.24. Tarsus Pharmaceuticals had a negative return on equity of 14.19% and a negative net margin of 9.02%.The business had revenue of $162.05 million during the quarter, compared to analysts’ expectations of $149.60 million. On average, equities analysts predict that Tarsus Pharmaceuticals, Inc. will post -0.59 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts recently issued reports on the stock. Lifesci Capital upgraded shares of Tarsus Pharmaceuticals to a “strong-buy” rating in a research note on Monday, March 16th. HC Wainwright restated a “buy” rating and set a $88.00 price objective on shares of Tarsus Pharmaceuticals in a research note on Monday, May 4th. Wall Street Zen upgraded shares of Tarsus Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday, June 6th. Guggenheim increased their price target on shares of Tarsus Pharmaceuticals from $87.00 to $90.00 and gave the company a “buy” rating in a report on Wednesday, February 25th. Finally, Zacks Research downgraded shares of Tarsus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, February 25th. Two research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $90.67.

View Our Latest Stock Report on TARS

Institutional Investors Weigh In On Tarsus Pharmaceuticals

Large investors have recently bought and sold shares of the business. Vanguard Group Inc. boosted its holdings in shares of Tarsus Pharmaceuticals by 5.6% during the 4th quarter. Vanguard Group Inc. now owns 2,399,560 shares of the company’s stock valued at $196,476,000 after acquiring an additional 127,470 shares during the last quarter. TimesSquare Capital Management LLC raised its stake in Tarsus Pharmaceuticals by 24.3% during the 4th quarter. TimesSquare Capital Management LLC now owns 332,446 shares of the company’s stock valued at $27,221,000 after buying an additional 64,941 shares during the last quarter. Citigroup Inc. increased its position in Tarsus Pharmaceuticals by 78.1% during the third quarter. Citigroup Inc. now owns 40,591 shares of the company’s stock valued at $2,412,000 after acquiring an additional 17,797 shares during the last quarter. Universal Beteiligungs und Servicegesellschaft mbH increased its position in Tarsus Pharmaceuticals by 19.9% during the fourth quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 109,857 shares of the company’s stock valued at $8,995,000 after acquiring an additional 18,267 shares during the last quarter. Finally, D.A. Davidson & CO. bought a new position in Tarsus Pharmaceuticals in the fourth quarter valued at about $1,493,000. 90.01% of the stock is currently owned by institutional investors.

Tarsus Pharmaceuticals Company Profile

(Get Free Report)

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.

Featured Stories

Insider Buying and Selling by Quarter for Tarsus Pharmaceuticals (NASDAQ:TARS)

Receive News & Ratings for Tarsus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tarsus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.